CHEMOPREVENTION OF PROSTATE CANCER WITH FINASTERIDE, PHASE III INTERGROUP

使用非那雄胺化学预防前列腺癌，第三阶段 INTERGROUP

• 批准号: 3740339
• 负责人: MICHAEL B ATKINS
• 金额: --
• 依托单位: TUFTS MEDICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3740339
• 关键词: chemoprevention; dihydrotestosterone; drug screening /evaluation; enzyme inhibitors; human subject; prostate neoplasms

Prostate cancer is the most common cancer in men, with 132,000 newly diagnosed cases per year and 34,000 deaths expected per year. Prostate cancer morbidity and mortality rates have risen, particularly in the African-American population, despite careful attention to early detection. Finasteride, a synthetic alpha-5 reductase inhibitor, inhibits the conversion on testosterone into circulating dihydrotestosterone.

前列腺癌是男性最常见的癌症，新增13.2万人 每年确诊病例和预计每年34,000例死亡。前列腺 癌症发病率和死亡率有所上升，特别是在 非洲裔美国人人口，尽管对早期 侦测。非那雄胺，一种人工合成的α-5还原酶抑制剂， 抑制睾酮转化为循环 双氢睾丸素。